Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer

Read the full 201 word article

User Sign In